Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative carboplatin chemoradiotherapy versus radiotherapy alone for high-risk cutaneous squamous cell carcinoma of the head and neck
ACTRN12607000146493Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Apr 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of carboplatin in cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Loco-regional relapse. Started Apr 2005; status: completed.
02
Drugs
carboplatin
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on ACTRN12607000146493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000146493.